Chemotherapy for bone sarcomas in adults: the MD anderson experience.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 20. Bull Cancer. 2025 Jun;112(6):601-610. doi: 10.1016/j.bulcan.2024.03.010. Epub 2025 Apr 10. [Recurrent or refractory Osteosarcoma and Ewing sarcoma-French guidelines from the FSG/NETSARC and GroupOs groups]. [Article in French] Brahmi M(1), Toulmonde M(2), Winter S(3), De Percin S(4), Valentin T(5), Corradini N(6), Gantzer J(7), Marec-Berard P(6), Gouin F(8), Claude L(9), Ducassou A(10), Gaspar N(11), Tlemsani C(4), Berlanga P(12); GroupOs (Groupe de travail multidisciplinaire des tumeurs osseuses français). Author information: (1)Department of medical oncology, centre Léon-Bérard, Lyon, France. (2)Department of medical oncology, Institut Bergonié, Bordeaux, France. (3)SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), Institut Curie, PSL research university, Paris, France. (4)Department of medical oncology, Cochin hospital, Paris, France. (5)Department of medical oncology, Institut Claudius Regaud, Toulouse, France. (6)Paediatric haematology-oncology Institut, centre Léon-Bérard, Lyon, France. (7)Department of medical oncology, hôpitaux universitaires de Strasbourg, Strasbourg, France. (8)Surgery department, centre Léon-Bérard, Lyon, France. (9)Department of radiation oncology, centre Léon-Bérard, Lyon, France. (10)Radiotherapy department, Institut Claudius-Regaud, institut universitaire du cancer Toulouse Oncopole, Toulouse, France. (11)Department of pediatric and adolescent oncology, Gustave-Roussy Cancer Campus, université Paris-Saclay, Villejuif, France. (12)Department of pediatric and adolescent oncology, Gustave-Roussy Cancer Campus, université Paris-Saclay, Villejuif, France. Electronic address: pablo.berlanga@gustaveroussy.fr. Osteosarcoma (OS) and Ewing Sarcoma (ES) are the two most frequent malignant bone tumors in children, adolescents and young adults. In case of disease recurrence, both are characterized by an aggressive behaviour and a relatively poor overall survival rate, with approximately a third of patients having a long-term disease-free survival. In case of recurrent or refractory (R/R) disease, the therapeutic strategy should be discussed in multidisciplinary staff meetings with expertise in bone sarcoma management. The standard management of R/R OS depends on the disease-free interval and the number and sites of metastases and is primarily surgical in patients with isolated lung metastases or local relapse. On the other hand, conventional chemotherapy remains the standard for R/R ES and include high-dose ifosfamide, cyclophosphamide with topotecan and irinotecan with temozolomide. Copyright © 2025. Published by Elsevier Masson SAS. DOI: 10.1016/j.bulcan.2024.03.010